Takanori Sasaki

Takanori Sasaki

Auto-generated profile, based on publicly available information

Takanori Sasaki

Division of Rheumatology, Inflammation, Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2022 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
TSTakanori Sasaki
Takanori Sasaki
SBSabrina Bracero
Sabrina Bracero
JKJoshua Keegan
Joshua Keegan
LCLin Chen
Lin Chen
YCYe Cao
Ye Cao
DRDeepak A. Rao
Deepak A. Rao

7 August 2021 in Rheumatology
Verified
Journal Article
Closed access
PDF file
TSTakanori Sasaki
Takanori Sasaki
MAMitsuhiro Akiyama
Mitsuhiro Akiyama
YKYuko Kaneko
Yuko Kaneko
TTTsutomu Takeuchi
Tsutomu Takeuchi
IgG4-related disease (IgG4-RD) and idiopathic multicentric Castleman’s disease (iMCD) are both rare systemic immune-mediated disorders. However, the pathogenesis differs markedly between the two diseases and differing therapeutic strategies are adopted: IgG4-RD is treated using a moderate dose of glucocorticoids or rituximab, while iMCD therapy involves an IL-6-targeted approach. Nonetheless, some clinical features of IgG4-RD and iMCD overlap, so differential diagnosis is sometimes difficult, even though the classification and diagnostic criteria of the diseases require careful exclusion of the other. The key findings in IgG4-RD are high IgG4:IgG ratio, allergic features and germinal centre expansion involving T follicular helper cells, while iMCD involves polyclonal antibody production (high IgA and IgM levels), sheet-like mature plasma cell proliferation and inflammatory features driven by IL-6. The distribution of organ involvement also provides important clues in both diseases. Particular attention should be given to differential diagnosis using combined clinical and/or pathological findings, because single features cannot distinguish IgG4-RD from iMCD. In the present review, we discuss the similarities and differences between IgG4-RD and iMCD, as well as how to distinguish the two diseases.

7 November 2020 in Rheumatology
Verified
Journal Article
Closed access
STSatoshi Takanashi
Satoshi Takanashi
JKJun Kikuchi
Jun Kikuchi
TSTakanori Sasaki
Takanori Sasaki
MAMitsuhiro Akiyama
Mitsuhiro Akiyama
HYHidekata Yasuoka
Hidekata Yasuoka
TTTsutomu Takeuchi
Tsutomu Takeuchi
Objective: To clarify relevant proteins and clinical characteristics of a phenotype of IgG4-related disease (IgG4-RD) with lymphadenopathy.Methods: We enrolled patients newly diagnosed with IgG4-RD in our department between January 2000 and June 2018 and performed proteomic analysis to measure serum concentrations of 1305 proteins. We extracted proteins overexpressed in patients with IgG4-RD with lymphadenopathy by comparing between those with lymphadenopathy, those without lymphadenopathy and healthy controls. We further reviewed all the patients with IgG4-RD in our institution and investigated the characteristics and prognosis of the patients with IgG4-RD with lymphadenopathy.Results: Eighty-five patients with IgG4-RD were enrolled, of which, 55% had lymphadenopathy. Proteomic analysis in 31 patients with IgG4-RD and 6 healthy controls revealed that eotaxin-3 was a potential serum biomarker in the patients with lymphadenopathy versus those without lymphadenopathy and healthy controls. A cohort of 85 patients with IgG4-RD demonstrated that patients with lymphadenopathy showed a significantly higher serum IgG4, IgG4:IgG ratio, IgG4-RD responder index and eosinophilia (P < 0.001 for all), irrelevant of the extent to which organ involvement developed. Patients with lymphadenopathy treated with glucocorticoid alone relapsed with significantly higher rates than those without lymphadenopathy (P = 0.03).Conclusion: Lymphadenopathy in IgG4-RD represents a phenotype associated with high disease activities, eosinophilia and relapsing disease. Eotaxin-3 is a novel biomarker related to IgG4-RD with lymphadenopathy.

4 September 2020 in Rheumatology
Verified
Journal Article
Closed access
HYHiroki Yamada
Hiroki Yamada
TSTakanori Sasaki
Takanori Sasaki
KMKotaro Matsumoto
Kotaro Matsumoto
KSKatsuya Suzuki
Katsuya Suzuki
MTMasaru Takeshita
Masaru Takeshita
TTTsutomu Takeuchi
Tsutomu Takeuchi
Objectives: PD-1hi CXCR5– T peripheral helper (Tph) cells are newly identified pathogenic CD4 helper T cells in RA. We evaluated the usefulness of Tph cell subsets as biomarkers of RA.Methods: RA patients who visited our rheumatology department between May 2015 and September 2017 and met the 2010 ACR/EULAR classification criteria were included. We compared the correlation of DAS28-ESR between Tph cell subsets and 40 immune cell subsets. We also explored which subsets reflected the chronological changes in the disease activity after treatment.Results: Thirty-four seropositive RA patients, 11 seronegative RA patients and 34 healthy controls were included. Tph cell subsets that correlated with the DAS28-ESR were HLA-DR+ Tph cells (rs = 0.50, P = 0.002), HLA-DR– Tph cells (rs = 0.39, P = 0.03) and Tph1 cells (rs = 0.41, P = 0.02). Among the other 40 immune cell subsets, HLA-DR+ Th1-17 cells (rs = 0.38, P = 0.03), activated B cells (rs = –0.35, P = 0.04), plasma cells (rs = 0.43, P = 0.01) and CD14++ CD16+ monocytes (rs = 0.36, P = 0.04) correlated, but not strongly as HLA-DR+ Tph cells. However, MTX treatment reduced the proportion of HLA-DR+ Tph cells independently of the disease activity. In contrast, HLA-DR– Tph cells accurately reflected the change in the DAS28-ESR during MTX treatment.Conclusion: HLA-DR+ Tph cells were decreased with MTX treatment, independent of the disease activity, while HLA-DR– Tph cells reflected the disease activity accurately during the treatment.

3 May 2024 in ACR Open Rheumatology
Verified
Journal Article
Open access
MEMehreen Elahee
Mehreen Elahee
AMAlisa A. Mueller
Alisa A. Mueller
RWRunci Wang
Runci Wang
KMKathryne E. Marks
Kathryne E. Marks
TSTakanori Sasaki
Takanori Sasaki
DRDeepak A. Rao
Deepak A. Rao
Objective: T cells contribute to tissue injury in systemic sclerosis (SSc), yet the specific T cell subsets expanded in patients with SSc remain incompletely defined. Here we evaluated specific phenotypes and functions of peripheral helper T (Tph) and follicular helper T (Tfh) cells, which have been implicated in autoantibody production, and assessed their associations with clinical features in a well‐characterized cohort of patients with SSc.Methods: Mass cytometry of T cells from peripheral blood mononuclear cells of patients with SSc and controls were evaluated using t‐distributed stochastic neighbor embedding visualization, biaxial gating, and marker expression levels. Findings were validated with flow cytometry and in vitro assays.Results: The frequencies of PD‐1highCXCR5+ Tfh cells and PD‐1highCXCR5− Tph cells were similar in patients with SSc and controls. t‐distributed stochastic neighbor embedding visualization (tSNE) revealed distinct populations within the PD‐1highCXCR5− cells distinguished by expression of HLA–DR and inducible costimulator (ICOS). Among PD‐1highCXCR5− cells, only the HLA–DR+ICOS− cell population was expanded in patients with SSc. Cytometric and RNA sequencing analyses indicated that these cells expressed cytotoxic rather than B cell helper features. HLA–DR+ICOS− PD‐1highCXCR5− cells were less potent in inducing B cell plasmablast differentiation and antibody production than comparator T helper cell populations. HLA–DR+ICOS−PD‐1highCXCR5− cells were significantly associated with the presence and severity of interstitial lung disease among patients with SSc.Conclusion: Among PD‐1highCXCR5− T cells, a subset of HLA–DR+ICOS− cells with cytotoxic features is specifically expanded in patients with SSc and is significantly associated with interstitial lung disease severity. This potential cytotoxicity appearing in the CD4 T cell population can be evaluated as a prognostic disease biomarker in patients with SSc.

6 December 2012 in Journal of Radioanalytical and Nuclear Chemistry
Verified
Journal Article
Open access
PDF file
TTTeruaki Toyota
Teruaki Toyota
THTadashi Hanafusa
Tadashi Hanafusa
TOTakashi Oda
Takashi Oda
IKIwane Koumura
Iwane Koumura
TSTakanori Sasaki
Takanori Sasaki
TOToshiro Ono
Toshiro Ono
Ion exchange is a simple and efficient method for separating no-carrier-added 64Cu from an irradiated Ni target. We developed a semi-automated two-round 64Cu separation system equipped with a strong-base anion exchange resin column. We first verified the efficiency of the system using a non-radioactive substitute consisting of 25 mg of Ni and 127 ng of Cu, and confirmed that Cu was completely eluted at the second round of the separation step. After the bombardment, separation of 64Cu from the Ni target was achieved with high radiochemical purity. 64Cu produced and separated in this study had an extremely low level of Ni impurity. It could be used for labeling monoclonal antibodies for antibody positron emission tomography imaging and synthesizing radiopharmaceuticals.